Post by Promega Corporation

What drives a decades-long screening program to change its core methodology? The NCI-60 is a preclinical screening platform designed to identify potential anti-cancer compounds across a broad spectrum of human cancers. The panel has shifted methodology over the years to keep up with changes in our understanding of cancer biology. Each shift driven by the same question: What is the best tool to be measure cell viability? The standard for cell health assays has evolved. Here's how that evolution played out at the largest cancer drug screening program in the world: https://ow.ly/xh1J50ZcWKJ

Video Content